Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients With Progressing Desmoid Tumors

Next Previous
X
Search
Trial Profile

RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients With Progressing Desmoid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 19 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BMS 986115 (Primary)
  • Indications Fibroma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms RINGSIDE
  • Sponsors Ayala Pharmaceuticals; Immunome

    • Most Recent Events

    • 13 Nov 2024 According to an Immunome media release, full enrollment for the Phase 3 RINGSIDE Part B study of AL102 for the treatment of desmoid tumors was completed in February 2024.
    • 26 Sep 2024 Planned End Date changed from 25 Feb 2025 to 1 Oct 2026.
    • 26 Sep 2024 Planned primary completion date changed from 15 Jan 2025 to 1 Oct 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top